If you have questions, please call us for more information about clinical trials or use our online form.

Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.  

Displaying 1 - 6 of 6

Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers

Objective
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Participants with Advanced Melanoma or Squamous Cell Head and Neck Cancer
Protocol No
SWOG-S2101
Categories
Cancer, Melanoma, Skin, Lip, Oral Cavity and Pharynx, Skin Cancers, Head and Neck Cancers

A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanced or Metastatic Sol

Objective
A Phase 1A 1B Study of TEV-56278 in Patients with Selected Locally Advanced or Metastatic Solid Tumors
Protocol No
TEVA-TV56278-ONC-10203
Categories
Cancer, Bladder, Lung, Cervix, Lip, Oral Cavity and Pharynx, Gastrointestinal Cancers, Other Skin, Larynx, Kidney, Melanoma, Skin, Gynecologic Cancers, Thoracic Cancers, Skin Cancers, Breast Cancers, Head and Neck Cancers, Prostate and Urologic Cancers

A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Subjects with KRAS G12C Mutant Advanced Solid Tumors

Objective
This project is being done to test the safety and tolerability of MK-1084 alone in combination with pembrolizumab in patients with solid tumor cancers that have a mutated KRAS gene.
Protocol No
MERCK-MK1084-001
Categories
Cancer, Kidney, Other Skin, Thoracic Cancers, Sarcoma, Gastrointestinal Cancers, Cervix, Prostate and Urologic Cancers, Other Gynecologic, Breast Cancers, Ovary, Gynecologic Cancers, Head and Neck Cancers, Early Phase/Multiple Disease Site Cancers, Endocrine Cancers, Melanoma, Skin, Eye/Orbital Cancers, Skin Cancers

High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)

Objective
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer, Lip, Oral Cavity and Pharynx, Cervix, Melanoma, Skin, Skin Cancers, Prostate and Urologic Cancers, Breast Cancers, Other Gastrointestinal, Gynecologic Cancers, Thoracic Cancers, Pancreas/Liver, Esophagus, Colorectal, Endocrine Cancers, Gastrointestinal Cancers, Sarcoma, Larynx, Brain and Spine Cancers, Head and Neck Cancers

A Multi-Center Observational Trial of Symptomatic, High-Risk Bone Metastases Treated With Percutaneous Ablation and Palliative Radiation Therapy

Objective
Trial of Symptomatic, High-Risk Bone Metastases Treated with Percutaneous Ablation and Palliative RT
Protocol No
SIO-TRIBUTE
Categories
Cancer, Prostate and Urologic Cancers, Uterine, Cervix, Melanoma, Skin, Gastrointestinal Cancers, Lung, Breast Cancers, Head and Neck Cancers, Skin Cancers, Endocrine Cancers, Gynecologic Cancers, Thoracic Cancers, Sarcoma, Brain and Spine Cancers, Eye/Orbital Cancers